DuCLOX-2/5 inhibition: a promising target for cancer chemoprevention

Breast Cancer. 2017 Mar;24(2):180-190. doi: 10.1007/s12282-016-0723-2. Epub 2016 Aug 24.

Abstract

Cancer is a leading cause of death and major health concern worldwide. The animal and human studies support the presumption that inflammation directs the cancer initiation and progression. Cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) are the key players in the inflammatory cascade contributing towards the angiogenesis, tumor cell invasiveness, and disruption in the pathways of cellular proliferation/apoptosis. Contemporary studies have particularized a promising role of COX-2 and 5-LOX inhibitors in cancer chemoprevention. The present review is a pursuit to define implications of dual COX-2 and 5-LOX (DuCLOX-2/5) inhibition on various aspects of cancer augmentation and chemoprevention.

Keywords: Angiogenesis; Apoptosis; Cyclooxygenase; Lipoxygenase; NSAIDs; Proliferation.

Publication types

  • Review

MeSH terms

  • Animals
  • Apoptosis / drug effects
  • Arachidonate 5-Lipoxygenase / metabolism*
  • Arachidonic Acid / metabolism
  • Cyclooxygenase 2 / metabolism
  • Cyclooxygenase 2 Inhibitors / pharmacology*
  • Humans
  • Lipoxygenase Inhibitors / pharmacology*
  • Molecular Targeted Therapy / methods*
  • Neoplasms / blood supply
  • Neoplasms / drug therapy*
  • Neoplasms / metabolism
  • Neoplasms / pathology
  • Neovascularization, Pathologic / drug therapy
  • Neovascularization, Pathologic / metabolism

Substances

  • Cyclooxygenase 2 Inhibitors
  • Lipoxygenase Inhibitors
  • Arachidonic Acid
  • Arachidonate 5-Lipoxygenase
  • Cyclooxygenase 2
  • PTGS2 protein, human
  • ALOX5 protein, human